摘要
目的：研究双相广谱抗癌新药康莱特注射液缓解癌痛及提高晚期癌症患者生存质量的作用。方法：本课题采用多中心协作，汇集我国１４家肿瘤医院３７６例晚期癌症患者临床治疗资料，其中伴有癌症疼痛患者３２８例，占８７２３％（３２８／３７６）。每位患者给予康莱特１００ｍｌｉｖｑｄ×２０天，观察治疗前后疼痛缓解，生活质量改善、免疫功能变化及不良反应。结果：癌症疼痛控制总有效率达８０４９％（部分缓解５６１０％，完全缓解２４３９％），用药结束后疼痛缓解仍可维持１～７天以上，且无成瘾性。在３７６例晚期癌症患者中，经康莱特治疗后９０％以上的晚期患者生存质量可以提高，并有提高机体免疫功能及升高外周血象作用。对康莱特不良反应观察，发现其对心、肝、肾功能无明显损害，约２５％的患者伴有轻度静脉炎。结论：康莱特在控制癌痛中可部分或全部替代吗啡类止痛药物。
Cancer pain management with pallative care of advanced cancer
patients is one of the four priorities of the comprehensive WHO Cancer Control Programme This
study was carried out by clinical observation to evaluate the effect of the new drug-Kanglaite
injection The clinical observation of 376 cases of advanced cancer patients who received
Kanglaite injection was completed on a multi-institutional cooperative basis in 14 cancer
hospitals in China Of these patients, 328 had cancer pain Each patient received Kanglaite
injection at the dose of 100ml daily iv for 20 days The degree of pain relief, improvement of
QOL and changes of immunological function were observed before and after treatment The
results indicated that the total cancer pain relief rate was 8049%(PR 5610%+CR 2439%) In some
cases, Kanglaite injection partially or completely replaced morphine which had been given
before study for pain Analgesic effect might persist for 17 days after withdrawal of Kanglaite No
psychological dependence was not advanced cancer patients had their QOL improved as well
as immunological function and peripheral blood picture elevated Approximately 25%of the
patients developed phlebitis No cardiac, liver or renal function damage were seen90%of the 376
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1999年第5期372-376,共5页
Chinese Journal of Clinical Oncology
关键词
康莱特
癌痛
生活质量
治疗
Kanglaite Cancer pain Life qualityed,
